Please login to the form below

Not currently logged in
Email:
Password:

Neurocrine plans movement disorder drug filing in 2016

NBI-98854 in trials for tardive dyskinesia
Neurocrine

Neurocrine Biosciences saw its share rise steeply yesterday after it reported positive results for a movement disorder drug that has been tipped as a potential blockbuster.

NBI-98854 is a vesicular monoamine transporter-2 (VMAT2) inhibitor in trials for tardive dyskinesia, a movement disorder known to affect patients with underlying schizophrenia, schizoaffective disorder, bipolar or major depressive disorder.

Around 500,000 people in the US suffer from TD, which often develops as a complication of psychoactive drugs, and Neurocrine is vying to be the first company to bring a treatment for the condition to market.

Its main rival is Teva, which is aiming to bring its deutetrabenazine (SD-809) candidate - another VMAT2 inhibitor - to market next year.

The results of the KINECT 3 study showed that patients treated with an 80mg dose of NBI-98854 showed a statistically significant improvement from baseline in the Abnormal Involuntary Movement Scale (AIMS) compared to placebo after six weeks' treatment.

The AIMS scores in the intent-to-treat population were reduced by an average of 3.1 points more than placebo, almost exactly the same improvement reported by Teva in its recently-reported study.

Neurocrine's chief executive Kevin Gorman said the KINECT-3 trial completes its placebo-controlled trials programme for NBI-98854 and - after the company completes an ongoing open-label safety trial called KINECT 4 - it will file for approval of the drug in 2016.

Analysts at Nomura recently predicted that NBI-98854 could eventually become a $1.5bn product, even without a possible follow-up indication in Tourette's syndrome - and the announcement of the phase III data sparked a 12% increase in its shares to top $43. This time last year the stock was trading at around $15.

Neurocrine expects to complete its first phase Ib trial in Tourette's shortly, with a placebo-controlled trials programme due start later this year.

Article by
Phil Taylor

9th October 2015

From: Research

Share

Tags

Featured jobs

Subscribe to our email news alerts

PMHub

Add my company
Cello Health Insight

Cello Health Insight is the global market research arm of Cello Health. With 35 years’ sector experience, we specialise in...

Latest intelligence

Theresa Heggie
Alnylam’s big moment: bringing groundbreaking RNAi drugs to Europe
Theresa Heggie talks about the biotech’s 16-year path to market, and the promise of its ‘gene silencing’ medicines...
patients
Retaining reader value in plain language summaries of clinical studies
Balancing the risk of misinterpretation with the public’s ability to understand simplified plain-language summaries...
Can we talk about the ego-bias and chemicals influencing your target audience’s behaviour?
Over the Summer, the Page & Page team became fascinated by two books on this very subject. Two books from one author, Dean Burnett, an eminent neuroscientist, lecturing at Cardiff...

Infographics